After the report of Kurtzke and Berlin 5 of quite beneficial results with isoniazid in 30 patients with multiple sclerosis, neurologists of the Veterans Administration organized a rigorous therapeutic trial in October 1954. Patients were assigned to placebo or isoniazid therapy in a doubleblind, randomized cooperative trial in 11 VA hospitals. After 14 months, the series of 186 patients (98 on placebo and 88 on isoniazid) provided 122 with follow-up of nine months or more. Detailed analysis of the observations provided only a mass of negative data, and it was concluded 11 that isoniazid has no beneficial effect on the course of multiple sclerosis.Eighteen months after initiation of the trial, treatment was stopped, but arrangements were made to continue the follow-up of the series at annual intervals. Although small, the series was quite carefully selected and studied at the outset, and the expectation was that continued follow-up might
Five-Year Follow-Up On Multiple Sclerosis: Report on Veterans Administration Cooperative Study. Arch Neurol. 1964;11(6):583–592. doi:10.1001/archneur.1964.00460240015002
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: